股本结构
单位：万股
| 公告日期 | 2024-03-28 | 2023-10-16 | 2023-11-09 | 2023-07-03 | 2023-08-14 | 2023-03-20 |
|---|---|---|---|---|---|---|
| 证券总股本 | 1420.47 | 1125.45 | 1240.47 | 1181.85 | 1182.09 | 1104.98 |
| 普通股本 | 28409.47 | 22508.98 | 24809.47 | 23636.95 | 23641.82 | 22099.62 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2023-12-31 | 2023-10-11 | 2023-09-30 | 2023-07-03 | 2023-06-30 | 2022-12-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
，当前存托凭证比例为：20
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-03-28 | 28409.47 | 未披露 |
更多>>
From January 1, 2023 to December 31,2023
Issuance of shares, net of issuance costs
Sale of treasury share at cost
|
2023-12-31 |
| 2023-10-16 | 22508.98 | 未披露 | 定期报告 | 2023-10-11 |
| 2023-11-09 | 24809.47 | 未披露 | 定期报告 | 2023-09-30 |
| 2023-07-03 | 23636.95 | 未披露 | 定期报告 | 2023-07-03 |
| 2023-08-14 | 23641.82 | 未披露 | 定期报告 | 2023-06-30 |
| 2023-03-20 | 22099.62 | 未披露 |
更多>>
From January 1, 2022 to December 31, 2022
Treasury share at cost
Exercise of options
Issuance of shares, net of issuance costs
|
2022-12-31 |
| 2022-11-10 | 22901.54 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Exercise of options
|
2022-09-30 |
| 2022-08-12 | 22863.31 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Exercise of options
|
2022-06-30 |
| 2022-03-30 | 22809.03 | 未披露 | 定期报告 | 2022-03-24 |
| 2022-01-05 | 22809.03 | 未披露 | 定期报告 | 2022-01-04 |
| 2022-03-30 | 22809.03 | 未披露 |
更多>>
From January 1, 2021 to December 31, 2021
Effect of reverse capitalization transaction
Issuance of shares and warrants, net of issuance costs
Exercise of options
|
2021-12-31 |
| 2021-11-12 | 22801.51 | 未披露 | 定期报告 | 2021-11-12 |
| 2021-08-13 | 22795.61 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of shares, net of issuance costs
|
2021-06-30 |
| 2021-06-14 | 22005.81 | 未披露 | 定期报告 | 2021-06-14 |
| 2021-05-13 | 21395.99 | 未披露 |
更多>>
From January 1, 2021 To March 31, 2021
Effect of reverse capitalization transaction
Issuance of shares and warrants, net of issuance costs
|
2021-03-31 |
| 2021-03-17 | 21395.95 | 未披露 |
更多>>
On March 16, 2021, Anchiano completed the Merger pursuant to the Merger Agreement. In connection with the Merger, and following the effective time of the Merger (the “Effective Time”), the Company effected a reverse share split of the Company’s ordinary shares at a ratio of 4:1 (the “Reverse Split”) and increased the number of ordinary shares per ADS from 5 to 20. Following the Reverse Split and closing of the Merger there are approximately 10,697,975 issued and outstanding ADSs of the Company outstanding, with pre-merger Chemomab shareholders owning approximately 90% and pre-merger Anchiano shareholders owning approximately 10% of the Company.
|
2021-03-17 |
| 2019-03-25 | 3709.94 | 未披露 | 定期报告 | 2019-03-25 |
| 2019-02-13 | 3709.94 | 未披露 |
更多>>
1.ADSs offered 2,652,174 ADSs
2. The number of ordinary shares to be outstanding after this offering is based on 15,575,682 ordinary shares outstanding as of February 1, 2019
|
2019-02-12 |
| 2019-01-07 | 1557.57 | 未披露 | 定期报告 | 2018-09-30 |
From January 1, 2023 to December 31,2023
Issuance of shares, net of issuance costs
Sale of treasury share at cost
From January 1, 2022 to December 31, 2022
Treasury share at cost
Exercise of options
Issuance of shares, net of issuance costs
From June 30, 2022 to September 30, 2022
Exercise of options
From March 31, 2022 to June 30, 2022
Exercise of options
From January 1, 2021 to December 31, 2021
Effect of reverse capitalization transaction
Issuance of shares and warrants, net of issuance costs
Exercise of options
From March 31, 2021 to June 30, 2021
Issuance of shares, net of issuance costs
From January 1, 2021 To March 31, 2021
Effect of reverse capitalization transaction
Issuance of shares and warrants, net of issuance costs
On March 16, 2021, Anchiano completed the Merger pursuant to the Merger Agreement. In connection with the Merger, and following the effective time of the Merger (the “Effective Time”), the Company effected a reverse share split of the Company’s ordinary shares at a ratio of 4:1 (the “Reverse Split”) and increased the number of ordinary shares per ADS from 5 to 20. Following the Reverse Split and closing of the Merger there are approximately 10,697,975 issued and outstanding ADSs of the Company outstanding, with pre-merger Chemomab shareholders owning approximately 90% and pre-merger Anchiano shareholders owning approximately 10% of the Company.
1.ADSs offered 2,652,174 ADSs
2. The number of ordinary shares to be outstanding after this offering is based on 15,575,682 ordinary shares outstanding as of February 1, 2019